Clinical Trials | A Phase 1, Open-Label, Dose-Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Combination of CLBR001, an Engineered Autologous T Cell Product, and ABBV-461, an Antibody-Based Biologic, in Subjects with Locally Advanced or Metastatic Breast Cance

The University of Virginia is seeking adults over the age of 18 who have locally advanced or metastatic breast cancer for a research study. This study will evaluate the safety and effectiveness of CAR-T study treatment for patients with locally advanced or metastatic breast cancer with investigational agents: CLBR001 and ABBV-461. You may be eligible if: • You have been diagnosed with hormone receptor (HR)+ breast cancer, including estrogen receptor (ER) and progesterone receptor, human epidermal growth factor receptor 2 (HER2)+, or triple-negative breast cancer (TNBC) • You have been diagnosed with refractory or relapsed locally advanced or metastatic breast cancer • You have received prior standard treatments This study will involve blood draws, Electrocardiograms (ECG), Leukapheresis Procedure, computed tomography (CT) scans, and a hospital stay. Study-related procedures that go beyond your standard care will be provided at no cost to you or your insurance. Additional information can be found here: https://clinicaltrials.gov/study/NCT06878248 [email protected]